Immvention therapeutix enters strategic collaboration with novo nordisk to develop oral therapies for sickle cell disease and other chronic diseases

Durham, n.c., jan. 22, 2025 (globe newswire) -- immvention therapeutix, inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with novo nordisk a/s to co-develop oral therapies for sickle cell disease (scd) and other chronic conditions.
NVO Ratings Summary
NVO Quant Ranking